Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Oxaliplatin in Biliary Tract Cancer
NCT01234051Phase 2Unknown
- Sponsor
- Korean South West Oncology Group
- Start
- Nov 2010
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and oxaliplatin in biliary tract cancer (BTC), sponsored by Korean South West Oncology Group. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
docetaxeloxaliplatin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01234051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234051.